Finsterer J, Engelmayer E, Trnka E, Stiskal M
Neurological Department, Neurological Hospital Rosenhügel, Vienna, Austria.
Clin Neuropharmacol. 2000 Mar-Apr;23(2):110-3. doi: 10.1097/00002826-200003000-00009.
Although the exact pathogenesis of central pontine myelinolysis (CPM) is unknown, correction of hyponatremia, thyreotropin releasing hormone, plasmapheresis, and corticosteroids seem to be effective. Assuming intravenous immunoglobulins (IVIG) to also be effective in CPM, 0.4 g/kg body weight/d immunoglobulins were applied to a 48-year-old patient who developed CPM with double vision, dysarthria, dysphagia, and left-sided hemiparesis 3 weeks after spontaneous normalization of hyponatremia. After 5 days of IVIG, his symptoms markedly improved, confirmed by improvement in the Norris score (42%), Frenchay score (19%), Kurtzke score (20%), Disability score (54%), vital capacity (26%), and peak torque (69%). The promising clinical effect of IVIG was assumed to be caused by the reduction of myelinotoxic substances, the development of antimyelin antibodies, and the promotion of remyelination. In conclusion, IVIG appear to be a promising therapeutic option in CPM.
虽然中枢性桥脑髓鞘溶解症(CPM)的确切发病机制尚不清楚,但纠正低钠血症、促甲状腺激素释放激素、血浆置换和皮质类固醇似乎是有效的。假设静脉注射免疫球蛋白(IVIG)对CPM也有效,对一名48岁的患者应用了0.4 g/kg体重/天的免疫球蛋白,该患者在低钠血症自发恢复正常3周后出现了伴有复视、构音障碍、吞咽困难和左侧偏瘫的CPM。静脉注射免疫球蛋白5天后,他的症状明显改善,Norris评分(提高42%)、Frenchay评分(提高19%)、Kurtzke评分(提高20%)、残疾评分(提高54%)、肺活量(提高26%)和峰值扭矩(提高69%)的改善证实了这一点。IVIG有前景的临床效果被认为是由髓鞘毒性物质的减少、抗髓鞘抗体的产生以及髓鞘再生的促进所导致的。总之,IVIG似乎是CPM中一种有前景的治疗选择。